PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment

Cheng-Yu Chang1 Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan

https://orcid.org/0000-0002-7196-3504

Yi-Chun Lai2 Division of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan;3 Faculty of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Yu-Feng Wei4 School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan;5 Department of Internal Medicine, E-Da Cancer Hospital, Kaohsiung, Taiwan

https://orcid.org/0000-0002-6380-3527

Chung-Yu Chen6 Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan;7 College of Medicine, National Taiwan University, Taipei, Taiwan

Shih-Chieh Chang2 Division of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan;8 Department of Critical Care Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, TaiwanCorrespondence[email protected]

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date